Peptide Series: What to Know About AOD-9604

 Written and Medically reviewed by Dr. Dan Wool, NMD

 Arizona-licensed Naturopathic Physician and Gastroenterology Specialist

 Updated: February 26, 2026

Summary (tl;dr):

• What AOD-9604 Is and How It Works: AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH) — specifically amino acids 176–191 — engineered to target fat metabolism. Unlike full hGH, it does not raise IGF-1 levels or impact blood sugar, making it a more targeted option for metabolic support.
• Potential Benefits of AOD-9604: Research suggests AOD-9604 may promote fat breakdown (lipolysis), inhibit new fat formation (lipogenesis), and support lean body composition. Emerging animal studies also point to possible joint and cartilage benefits, particularly when paired with hyaluronic acid therapy.
• Safety, Regulatory Status, and Contraindications: AOD-9604 is not FDA-approved and has not completed large-scale human efficacy trials. Therefore, it is not appropriate most -- especially those who are pregnant, breastfeeding, have active cancer, or certain metabolic conditions. Medical oversight, proper sourcing, and lab monitoring are essential before and during use.
• What to Expect with Treatment: Most patients using AOD-9604 under medical supervision report gradual improvements in body composition over 8-12 weeks. It is typically administered as a daily subcutaneous injection, ideally on an empty stomach. Side effects are generally mild and short-lived.

Overview

If you have been following the buzz around peptide therapy — in wellness clinics, anti-aging circles, or your own social media feed — you have likely come across AOD-9604. It is billed as a fat-burning peptide that works more like a precision tool than a sledgehammer. But what is AOD-9604, really? And does the science back up the claims?

AOD-9604 stands for "Anti-Obesity Drug-9604." It is a synthetic peptide fragment taken from the C-terminal end of human growth hormone (hGH) — specifically, the stretch of amino acids at positions 176 through 191. Originally developed in Australia in the 1990s, it was designed to harness the fat-burning properties of growth hormone without triggering its broader hormonal effects. The result is a peptide that acts very selectively on fat cells — and, intriguingly, may offer some joint benefits — without the side effects commonly linked to full-length hGH therapy.

This article is part of Dr. Wool's Peptide Series. As with all peptides covered in this series, the goal is to give you a clear, honest, science-based picture — so you're not prone to all the misinformation out there. 

What Is AOD-9604?

To understand AOD-9604, it helps to understand growth hormone first. Human growth hormone (hGH) is produced by the pituitary gland. It plays a central role in how the body builds tissue, regulates metabolism, and maintains body composition. Among other things, hGH stimulates lipolysis — the breakdown of stored fat — and can help the body use fat as fuel.

The problem with full hGH therapy is that it does a lot of things at once. It raises IGF-1 levels (which can drive cell growth), can affect blood sugar regulation, and carries risks of promoting unwanted tissue proliferation. Researchers wanted to isolate just the fat-burning signal — and AOD-9604 was the result.

AOD-9604 consists of amino acids 176–191 of hGH, with a tyrosine modification at one end to improve stability and receptor binding. Critically, it does not bind to the growth hormone receptor and does not raise IGF-1 levels.[1] This means its effects stay localized to fat metabolism, making it a much more targeted option than full hGH therapy.

The peptide was developed by Metabolic Pharmaceuticals Ltd. and went through six human clinical trials involving over 900 participants. While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2]

Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health.

Potential Benefits of AOD-9604

Fat Breakdown and Body Composition

The core mechanism of AOD-9604 is dual: it stimulates lipolysis (the breakdown of stored fat into free fatty acids the body can use for energy) while simultaneously inhibiting lipogenesis (the conversion of excess calories into new fat stores). In animal studies, AOD-9604 reduced body weight gain by over 50% in obese mice during a 19-day treatment period, and significantly increased fat oxidation — all without affecting insulin sensitivity or glucose regulation.[1,3]

A randomized controlled trial in humans found that participants taking 1 mg of AOD-9604 daily lost an average of 2.8 kg (~6 lbs) over 23 weeks, compared to 0.8 kg (~1.7 lbs) in the placebo group. The results, while modest, were consistent with the peptide's selective mechanism.[4] The peptide appeared especially useful in the study for mobilizing visceral and abdominal fat — the type most resistant to traditional diet and exercise.

No Effect on IGF-1 or Blood Sugar

One of AOD-9604's most clinically relevant features may be what it doesn't do. Unlike full-length hGH, AOD-9604 has been found not to raise IGF-1 levels and does not affect insulin sensitivity. This may reduce concerns around cell proliferation and metabolic disruption — two of the primary safety concerns with hGH therapy.[1]

Emerging Joint and Cartilage Support

Beyond fat metabolism, early research points to potential joint health benefits. A 2015 study published in the Annals of Clinical and Laboratory Science found that intra-articular (injected into the joint) AOD-9604 enhanced cartilage regeneration in a rabbit model of knee osteoarthritis. When combined with hyaluronic acid, the results were even more significant — surpassing either treatment used alone.[5] While human joint trials are still lacking, this is a promising area of investigation, particularly for patients dealing with both excess weight and degenerative joint conditions.

Important Considerations for AOD-9604

AOD-9604 Is Not FDA-Approved

This bears repeating. AOD-9604 has not been approved by the FDA — or any major regulatory body — for human therapeutic use. It is available through compounding pharmacies for investigational and clinical off-label use, but it should only be sourced through a licensed, reputable compounding pharmacy under physician oversight. Do not buy it from unregulated online vendors or "research chemical" sites.

Mixed Clinical Efficacy

The clinical trial history of AOD-9604 is mixed. While early and smaller trials showed promising fat-loss effects, the largest Phase IIb trial did not achieve statistical significance in humans for its primary endpoint of weight reduction, which led to the program being discontinued. This does not mean it would be ineffective for every patient — but it does raise questions about expectations. As such, AOD-9604 may be best viewed as a supportive tool within a comprehensive metabolic plan, not a standalone weight loss solution.

Contraindications

AOD-9604 is not appropriate for everyone. One should not use AOD-9604 if they:

• Are pregnant or breastfeeding
• Are a minor
• Have a current or recent history of cancer (particularly hormone-sensitive cancers)
• Have uncontrolled diabetes or significant insulin resistance
• Have active thyroid disease that is not well-managed
• Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds

Comprehensive labs — including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels — should be run before starting any peptide therapy and monitored regularly throughout.

Beware of Peptide Mills

As with CJC-1295/Ipamorelin and other popular peptides in this series, AOD-9604 production and distribution has attracted its share of bad actors. Be wary of med spas, online supplement companies, and anyone offering peptide therapy without comprehensive bloodwork, a thorough intake evaluation, and ongoing monitoring. Peptides are not supplements. They exert real physiological effects. In the wrong hands — or with impure sourcing — they carry real risks.

What to Expect With Use of AOD-9604

Administration

AOD-9604 is typically administered as a subcutaneous injection — meaning a small injection into the fatty layer of skin, usually in the abdomen. The standard dosing range in clinical use is 250–500 mcg per day, administered in the morning on an empty stomach for best results, though some providers prescribe alternate protocols. Some compounding pharmacies also offer oral formulations, though absorption rates are lower with oral administration. Your prescriber will determine the right approach for your goals.

Timeline for Results

Patience is key. Most patients notice initial metabolic shifts — such as changes in energy or early body composition feedback — within two to four weeks. Visible body composition improvements typically take 8-12 weeks of consistent use. As with all peptide therapies, the body responds gradually, and results are most significant when AOD-9604 is paired with solid nutrition, regular movement, and adequate sleep.

Cycle Length

Most practitioners recommend cycles of 8-12 weeks, followed by a break. Because AOD-9604 does not raise IGF-1 and is not a growth hormone analog in the traditional sense, cycling requirements are less strict than with CJC-1295/Ipamorelin — but a provider should guide any protocol based on labs and a patient's overall goals.

Side Effects

AOD-9604 has a well-documented safety profile, with clinical trials involving over 900 participants showing good tolerability. Reported side effects are generally mild and may include:

• Redness, swelling, or discomfort at the injection site
• Mild headache
• Fatigue (usually short-lived)
• Minor and transient changes in blood sugar (rare)

AOD-9604 does not appear to cause the joint pain, fluid retention, or glucose dysregulation commonly seen with full hGH therapy. If any side effect persists or worsens, contact your prescriber promptly.

Natural Alternatives to AOD-9604

Dietary and lifestyle optimization remains the most powerful lever in weight loss. In fact, they're undefeated. Protein-forward, whole-food diets with a modest caloric deficit, combined with resistance training and adequate sleep, drive the same lipolysis pathways that AOD-9604 targets pharmacologically. For stubborn belly fat specifically, strategies that address cortisol, insulin sensitivity, and sleep quality can move the needle significantly. You cannot out-peptide these. 

Berberine, ALA, Omega 3s

Berberine is a plant-derived compound with evidence supporting improvements in insulin sensitivity, fat metabolism, and lipid profiles — addressing some of the same downstream metabolic issues that AOD-9604 targets. Alpha-lipoic acid (ALA) and omega-3 fatty acids may support similar metabolic pathways.

Collagen + Herbs

For joint health, collagen peptides (types I, II, and III), hyaluronic acid supplementation, and anti-inflammatory herbs such as turmeric and boswellia offer evidence-backed support for cartilage and joint comfort — particularly relevant if AOD-9604's joint benefits are among one's reasons for interest in it.

GLP-1 Peptide Medications

GLP-1 peptides -- such as semaglutide and tirzepatide -- may be a more clinically validated option for patients whose primary goal is meaningful weight loss, and these are addressed in separate articles in this Peptide Series.

If you are not a candidate for AOD-9604 — or want to support fat metabolism and body composition through non-peptide means first — these are meaningful options to discuss with your doctor.

Frequently Asked Questions about AOD-9604

1. Does AOD-9604 affect insulin or blood sugar levels?

Quick Answer: No. AOD-9604 does not appear to affect insulin sensitivity or blood sugar, which is one of its key advantages over full-length hGH therapy.

Full Answer: This is one of AOD-9604's most clinically important features. Unlike human growth hormone, which can induce hyperglycemia and reduce insulin secretion during extended use, AOD-9604 showed no adverse effect on insulin sensitivity even in long-term animal studies — confirmed through euglycemic clamp techniques. [1] This makes it a safer option for metabolically complex patients. That said, your provider should still establish a baseline with fasting glucose and HbA1c before starting, and monitor periodically throughout treatment.

2. Can AOD-9604 be combined with GLP-1 peptides like semaglutide or tirzepatide?

Quick Answer: Potentially yes — they work through different pathways and may be complementary — but this combination requires careful medical supervision and has not been studied in clinical trials.

Full Answer: GLP-1 agonists like semaglutide and tirzepatide primarily reduce body weight by suppressing appetite and improving insulin signaling. AOD-9604 works at the fat cell level, stimulating lipolysis and inhibiting lipogenesis through a completely separate mechanism. In theory, stacking them could address fat metabolism from two different angles. However, no clinical trials have evaluated this combination, and any multi-peptide or peptide-plus-GLP-1 protocol should be managed by a practitioner who can monitor labs, adjust doses, and watch for unexpected interactions.

3. How is AOD-9604 different from CJC-1295/Ipamorelin?

Quick Answer: CJC-1295/Ipamorelin stimulates your body to produce more growth hormone from the top down. AOD-9604 acts directly on fat cells and does not involve the GH axis at all.

Full Answer: CJC-1295/Ipamorelin works through the hypothalamus-pituitary pathway — essentially telling your brain to release more natural growth hormone. The benefits are broad: better muscle recovery, improved sleep, fat loss, and body composition over time. AOD-9604, by contrast, acts directly on adipose (fat) cells without touching the GH axis, and does not raise IGF-1. It is more targeted for fat metabolism specifically, but lacks the multi-system recovery and sleep benefits of CJC/Ipamorelin. Both can be used together under the right circumstances — your provider will guide whether that makes sense for your goals.

4. Can AOD-9604 help with joint pain or osteoarthritis?

Quick Answer: Maybe. Early animal research is promising — AOD-9604 injected into arthritic joints enhanced cartilage regeneration, especially when combined with hyaluronic acid. Human data is not yet available.

Full Answer: A 2015 study published in the Annals of Clinical and Laboratory Science found that ultrasound-guided intra-articular injections of AOD-9604 significantly improved cartilage regeneration in a rabbit knee osteoarthritis model. Combining AOD-9604 with hyaluronic acid produced even better outcomes than either treatment alone — with reduced lameness and lower cartilage degeneration scores. [5] This is an emerging area of interest, particularly for patients dealing with both excess weight and degenerative joint disease. No human clinical trials have evaluated AOD-9604 for osteoarthritis yet, so discuss the current evidence honestly with your provider before pursuing this specific application.

5. Why was AOD-9604 discontinued as a commercial drug if it showed promise?

Quick Answer: The largest Phase IIb trial (536 subjects, 24 weeks) did not hit statistical significance for weight loss — ending commercial development in 2007. That does not mean it is ineffective for the right patient.

Full Answer: AOD-9604 completed six human clinical trials involving over 900 participants, and its safety profile was consistently favorable. However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program. [2] The bar for FDA drug approval is extremely high, and many compounds that fall short of that bar still have meaningful clinical utility under medical supervision. AOD-9604 is a good example: its targeted mechanism, clean safety record, and emerging joint data continue to make it a useful tool in integrative and functional medicine settings.

6. Is AOD-9604 banned in sports?

Quick Answer: Yes. AOD-9604 is on the WADA prohibited list and can be detected in drug tests. Competitive athletes should not use it.

Full Answer: The World Anti-Doping Agency (WADA) classifies AOD-9604 as a prohibited substance under the category of peptide hormones, growth factors, and related substances. It can be detected in both plasma and urine using specialized LC/MS/MS assay methods for several days post-administration. Any competitive athlete subject to anti-doping testing — at any level — should not use AOD-9604. If you are a recreational athlete or non-competing fitness enthusiast, this prohibition does not apply to you directly, but it is worth knowing when evaluating claims made by coaches, trainers, or online vendors.

The Bottom Line on AOD-9604

AOD-9604 is a genuinely interesting peptide. It has been shown to target fat metabolism with a precision that full-length hGH cannot match, avoids many of hGH's most significant risks, and carries a well-characterized safety profile from over 900 clinical trial participants. Its Phase IIb stumble — failing to hit the statistical bar for commercial obesity treatment — does not erase its promise as a supportive, off-label tool within a carefully managed wellness program.

The key word is "managed." AOD-9604 is not a shortcut, and it is not for everyone. But for patients who have done the foundational work — diet, movement, sleep, lab optimization — and are still hitting a wall with fat metabolism or body composition, it may be a worthwhile piece of the puzzle. The emerging data on joint and cartilage support also makes it interesting for patients dealing with both metabolic and musculoskeletal concerns.

As always: work with a qualified practitioner who knows how to source it legally, dose it, monitor labs, and integrate it into a real, comprehensive health plan.

Ready to optimize your health? 

Dr. Dan Wool believes in the use of scientifically-backed peptide therapies when safe and indicated to enhance patient outcomes. If you're in the Phoenix or Scottsdale area, medical management of AOD-9604 from Dr. Wool may offer an option for those struggling with weight issues and stalled fitness goals. If these sound familiar, it may be time to explore a full health assessment with Dr. Wool. Book a free 15 Minute Discovery Call to understand how peptides might fit into your treatment plan to help restore balance from the inside out.

Disclaimer:

For educational purposes only — not medical advice, diagnosis, treatment or advertising for consumer purchase. Dr. Dan Wool and affiliates make no effectiveness claims about supplements, hormones, peptides or other therapeutics beyond cited clinical evidence and regulatory approval. Compounded peptide therapies may be prescribed off-label by licensed providers when clinically appropriate; they are not FDA-approved for general consumer use, retail sale or recreational self‑administration and are dispensed exclusively through licensed pharmacies to patients under active clinical care. Regulatory status varies across medical, retail and athletic contexts. Always consult a qualified healthcare provider before starting, changing, or stopping any medical or wellness program.

References:

[1] Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Obes Res. 2001;9(11):706–714. Retrieved from National Center for Biotechnology Information (NCBI), February 20, 2026. https://pubmed.ncbi.nlm.nih.gov/11673763/

[2] Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Ann N Y Acad Sci. 2000;921:262–272. Retrieved from NCBI, February 20, 2026. https://pubmed.ncbi.nlm.nih.gov/11146367/

[3] Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. Retrieved from NCBI, February 20, 2026. https://pubmed.ncbi.nlm.nih.gov/11713213/

[4] Wilding JP. AOD-9604. Curr Opin Investig Drugs. 2004 Apr;5(4):436–40. Retrieved from NCBI, February 20, 2026. https://pubmed.ncbi.nlm.nih.gov/15134286/

[5] Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426–432. Retrieved from NCBI, February 20, 2026. https://pubmed.ncbi.nlm.nih.gov/26275694/

Learn more about specific Peptides